{"version":"1.0","type":"rich","provider_name":"Acast","provider_url":"https://acast.com","height":250,"width":700,"html":"<iframe src=\"https://embed.acast.com/$/652558c78b631000124f5568/65c254adf377ea0017da5642?\" frameBorder=\"0\" width=\"700\" height=\"250\"></iframe>","title":"How does HS affect patients?","thumbnail_width":200,"thumbnail_height":200,"thumbnail_url":"https://open-images.acast.com/shows/652558c78b631000124f5568/1715957774370-d5b4a1d828d8f7335fbc1c0df7da819d.jpeg?height=200","description":"<p>This podcast is aimed at healthcare professionals, produced and funded by UCB.&nbsp;</p><p><br></p><p>For our second episode, our host Dr Barry McGrath is joined by Professor Falk Bechara, the Head of the Department of Dermatologic Surgery at the Ruhr University Bochum, Germany. Together, they discuss the profound physical, psychological and social impacts that hidradenitis suppurativa can have on a patient’s quality of life.&nbsp;&nbsp;</p><p>Please note, this episode briefly discusses suicide (20:28–22:35); listener discretion is advised.&nbsp;</p><p><br></p><p><strong>Speaker disclosures:</strong>&nbsp;</p><p>Dr Barry McGrath and Professor Falk Bechara have received consulting fees, research or institutional support and educational grants from UCB.&nbsp;</p><p>Barry McGrath, PhD, has received consultancy/advisory board disease-related honoraria from Novartis and UCB.&nbsp;&nbsp;</p><p>Falk G. Bechara has received honoraria for participation in advisory boards, in clinical trials, and/or as a speaker from AbbVie Inc., AbbVie Deutschland GmbH &amp; Co. KG, Boehringer Ingelheim Pharma GmbH &amp; Co. KG, Novartis Pharma GmbH, UCB Pharma, Incyte Corporation, Janssen-Cilag GmbH, MoonLake, Dr. Wolff, Mölnlycke and Celltrion.&nbsp;</p><p>© UCB Biopharma SRL, 2024. All rights reserved.&nbsp;</p><p>Date of preparation: January 2024&nbsp;</p><p>GL-DA-2400006&nbsp;&nbsp;</p>","author_name":"UCB Biopharma"}